Speaker(s): 

Emilie Detweiler, PharmD, PGY1 Pharmacy Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher DeFrancesco, PharmD, Clinical Pharmacist, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Describe patients presenting with serotonin syndrome and neuroleptic malignant syndrome

2. Understand the differences between serotonin syndrome and neuroleptic malignant syndrome

3. Review treatment regimens for serotonin syndrome and neuroleptic malignant syndrome

4. Apply information learned to future patients

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH, Anil Singh MD, Roop Parlapalli, MD, FHM, FACP, Mary Ellen Berry PA-C, and Carlena Miller CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None